The seizure frequency and VAS of breakthrough pain in group A decreased significantly after the treatment ( P < 0.05 ) and the general satisfaction was the best among the the 3 groups ( P < 0.05 ) , with less nausea and vomiting , constipation , drowsiness and fewer other side effects .